stockrow
Saturday 7 November 2026
Export CLDI’s income statement to Excel — free account
Calidi Biotherapeutics, Inc.
CLDI Healthcare Biotechnology
Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00.
- EPS
- +90.8%
- Free cash flow
- +11.2%
- Total debt
- −7.87%
Quarter to June 2026, against a year earlier
0.70
0.02
+2.94%
Follow CLDI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 68.89 | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | 3 | (25) | (29) | (22) | (20) | (17) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | (56,480.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | — | 3 | (25) | (29) | (22) | (20) | (18) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 10.23 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | 1,131.33 | (5,742.43) | (3,322.93) | (570.47) | (95.20) | (54.30) | n/m | ||||||
| Cash flow | — | — | — | — | — | (360.97) | (3,003.18) | (3,066.25) | (472.28) | (79.19) | (12.54) | (31.6%) | ||||||
| Capex | — | — | — | — | — | 0.00 | (97.27) | (66.48) | (0.38) | (0.45) | (0.07) | n/m | ||||||
| Free cash flow | — | — | — | — | — | (360.97) | (3,100.45) | (3,132.73) | (472.66) | (79.63) | (12.60) | (31.5%) | ||||||
| Book value | — | — | — | — | — | (4,895.60) | (11,463.64) | (935.80) | 47.19 | 13.98 | 2.21 | n/m | ||||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | +207.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | 0.00 | — | — | — | 0.32 | — | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | (6.52) | — | — | — | 0.07 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (13) | (27) | (20) | (21) | (18) | +110.6% | |||||
| Capex | — | — | — | — | — | — | 0 | (1) | 0 | 0 | 0 | (34.5%) | ||||||
| Free cash flow | — | — | — | — | — | (1) | (14) | (28) | (20) | (21) | (18) | +110.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | (42) | (6) | 1 | 2 | 2 | +21.3% | |||||
| Net debt | — | — | — | — | — | (1) | 1 | 0 | (9) | (5) | (3) | +46.0% | ||||||
| Shareholders’ equity | — | — | — | — | — | (15) | (50) | (8) | 2 | 4 | 3 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 2.92 | (21.70) | (463.16) | (196.80) | (222.05) | (283.36) | (225.0) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 78.08 | 99.59 | 759.98 | (893.28) | (900.56) | (893.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 2 | 2 | 41 | 28 | 29 | — | +95.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · fundamentals updated 26 Oct 2026
Calidi Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics Inc | $2.7M | — (loss-making) | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $2.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $2.6M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $2.5M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | |
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VIVS VivoSim Labs, Inc. | $2.3M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| HCWB HCW Biologics Inc. | $2.3M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| APVO Aptevo Therapeutics Inc. | $2.3M | — (loss-making) | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $2.4M | — | — | −51.35% | — | −9.86% | 0.00% | (527.99%) |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
4.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement